Cancer Cachexia Market Players:
- Pfizer, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Veru Inc.
- Eli Lilly and Company
- Bristol-Myers Squibb Company
- Mylan N.V.
- ANI Pharmaceuticals
- Novartis AG
- Hikma Pharmaceuticals Plc.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of cancer cachexia is assessed at USD 2.65 Billion.
The global cancer cachexia market size surpassed USD 2.54 Billion in 2025 and is projected to grow at a CAGR of around 4.7%, reaching USD 4.02 Billion revenue by 2035.
North America cancer cachexia market is anticipated to achieve a 30% share by 2035, driven by the rising prevalence of chronic illnesses like cancer and expanding knowledge of cachexia treatments.
Key players in the market include Veru, Inc, Eli Lilly and company, Bristol-Myers Squibb Company, Mylan N.V., ANI Pharmaceuticals, Novartis AG, Hikma Pharmaceuticals Plc., Sun pharmaceutical Industries Ltd.
